BioStock article: Aptahem’s Scientific Advisors on Sepsis Candidate Apta-1

BioStock published an article on 24 March 2021 about Aptahem, which can be read in full below. Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a life-threatening condition that is relatively unknown to the...

Read More

BioStock article: Aptahem’s CEO on signing of non binding Term Sheet

BioStock published an article on 10 March 2021 about Aptahem, which can be read in full below. Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a European pharmaceutical company. The NBTS...

Read More

Aptahem signs a non binding Term Sheet for development, manufacturing and distribution of Apta-1 for sepsis in Europe

Aptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license terms for exclusive development, manufacturing and distribution of...

Read More